Review
Open access
Sep 2026
Beyond Traditional Lipid Lowering: Obicetrapib and the Renaissance of Cholesteryl Ester Transfer Protein Inhibition
The results demonstrate that obicetrapib significantly reduces LDL cholesterol by 30–50%, apolipoprotein B by 20–30% and lipoprotein(a) by as much as 40-50%, while elevating HDL cholesterol levels by more than 100%.
P. Thandi, Akshyaya Pradhan, R. Agarwala et al.
· European Cardiology · 0 citations